| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Jupiter Neurosciences, Inc.$0.08
-0.02 (-24.03%)
Market Cap
3.77 M
EPS
-0.19
P/E Ratio
-
Value Trade
602.76 K
SEC Financials
Q1 2026Dilution Risk
Revenue
18.65 K
R&D Expenses
411.05 K
Operating CF
-1.43 M
Total Assets
3.95 M
Total Liabilities
6.73 M
Equity
-2.78 M
-20.96 %
Week
-64.62 %
1 Month
-78.44 %
3 Month
-85.69 %
6 Month
-94.06 %
5 Year
-94.06 %
All Time
Cash Data
Cash Position
2.36 M
Monthly Burn
477.00 K
Runway
2.3 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
4.60 M
52 Week Range
0.08 - 1.84
% held by Insiders
36.98 %
% held by Institutions
3.95 %
Enterprise Value
1.49 M
Total Shares
48.22 M
Short %
0.75 %
Float Shares
31.73 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Jupiter Neurosciences, Inc.
62Total events
6Upcoming
14Tier-1 (high impact)
2024 – 2026Coverage
Upcoming catalysts 2
TBD
T1Partnership / License
Subscribe to view catalyst details
TBD
T2Trial Completion
Subscribe to view catalyst details
Event history 2
TBD
▲Partnership / LicenseALA-002FiledCorporate
Subscribe to view catalyst details
TBD
▲Milestone PaymentALA-002FiledCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
JOTROL™ | Parkinson's Disease | Phase 2a | 2026-05-27 | statistically significant neuroprotective effects including rotarod performance and grip strength Read More | Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease Read More | |
JOTROL™ | Parkinson's Disease | Phase 2a | 2026-05-27 | statistically significant neuroprotective effects including rotarod performance and grip strength Read More | Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease Read More | |
JOTROL™ | Parkinson's Disease | Phase 2a | 2026-05-27 | statistically significant neuroprotective effects including rotarod performance and grip strength Read More | Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in JUNS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
JUNS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
JUNS▼ -24%today
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
Jupiter Neurosciences, Inc. has announced a 1-for-75 reverse stock split approved by shareholders to enhance its stock price for Nasdaq compliance. The split will take effect on August 6, 2026, and will reduce outstanding shares significantly. Stockholders will receive cash for any fractional shares resulting from the split, and the company continues to advance its pipeline in neurological therapies.
Read more →JUNSJupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Jupiter Neurosciences has signed a definitive agreement with PharmAla Biotech for exclusive U.S. rights to ALA-002, a patented MDMA formulation. This transaction, valued at up to $100 million, allows Jupiter to diversify its CNS portfolio, adding a novel chemical entity alongside its ongoing Parkinson's disease program. The deal includes various milestone payments and aims to address treatment-resistant neuropsychiatric conditions.
Read more →JUNSPharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
PharmAla Biotech has entered a definitive license agreement with Jupiter Neurosciences, granting exclusive U.S. rights to its lead drug candidate, ALA-002. The deal includes an upfront payment of $3.33 million and potential milestone payments totaling up to $100 million. PharmAla retains rights outside the U.S. and aims to advance ALA-002 internationally. This partnership is expected to enhance the development of ALA-002, targeting neuropsychiatric disorders.
Read more →JUNSJupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
Jupiter Neurosciences has appointed Dr. Tomas J. Philipson to its Board of Directors, effective June 26, 2026. Dr. Philipson, a former Acting Chairman of the White House Council of Economic Advisers, brings a wealth of experience in health economics and regulatory policy. His role is expected to enhance the company's strategic growth and shareholder value.
Read more →JUNSJupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
Jupiter Neurosciences has commenced patient enrollment for its Phase 2a RESET trial evaluating JOTROL™, an investigational treatment for Parkinson's Disease. This trial aims to address the unmet need for disease-modifying therapies, as current options only manage symptoms. The company anticipates first patient dosing soon, marking a significant milestone in their clinical development efforts.
Read more →JUNS▼ -12.2%on this newsshared move
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences has successfully closed a $2.0 million registered direct offering, enhancing its financial position to support its Parkinson's Phase 2a trial. The company has also reduced its debt, which strengthens its balance sheet. CEO Christer Rosén highlighted the importance of this funding for upcoming milestones and future financing opportunities.
Read more →JUNS▼ -35.9%on this newsshared move
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences, Inc. has announced a registered direct offering of 7,142,858 shares of common stock, aiming to raise approximately $2.0 million. The offering is expected to close around May 21, 2026, pending customary conditions. This funding will support the company's clinical-stage programs targeting central nervous system disorders.
Read more →JUNS▼ -35.9%on this newsshared move
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Ther
Jupiter Neurosciences, Inc. has announced a $100 million term sheet for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic from PharmAla Biotech. The transaction involves an upfront payment and outlines additional milestone payments tied to the drug's development and commercialization. ALA-002, recognized by the FDA as a Novel Chemical Entity, promises improved safety and therapeutic benefits. This acquisition positions JUNS strategically in the expanding market for psychedelic therapies, particularly for addressing conditions like PTSD and anxiety.
Read more →JUNS▼ -35.9%on this newsshared move
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
PharmAla Biotech has signed a term sheet granting exclusive U.S. rights to its MDMA therapeutic ALA-002 to Jupiter Neurosciences. The deal, valued at over $100 million, includes upfront payments and royalties. PharmAla retains rights outside the U.S. and aims to focus on its global strategy while benefiting from Jupiter's expertise in CNS therapies.
Read more →JUNSJupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board
Jupiter Neurosciences has appointed Kristopher Fishman and Sanjiv Lal to its Nugevia™ Advisory Board, bringing extensive experience in pharmacy and wellness distribution. Their expertise highlights the company's focus on the growing market for practitioner-grade nutraceuticals, valued at over $1.5 billion in the U.S. The Nugevia™ line includes formulations backed by JOTROL™, which has shown improved bioavailability in clinical studies. The appointments aim to strengthen Jupiter's market presence in compounding and wellness sectors.
Read more →JUNSJupiter Neurosciences to Present at Emerging Growth Conference on April 2
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) will present its clinical and commercial advancements at the Emerging Growth Conference on April 2, 2026. The company is focusing on neuroinflammation and healthy aging through its patented JOTROL™ platform. The presentation will be accessible live and via archived webcasts for investors and analysts.
Read more →JUNSJupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
Jupiter Neurosciences will present at the BIO Investment and Growth Summit 2026, discussing its FDA-cleared Phase IIa clinical program for Parkinson's disease. The company aims to engage with investors while advancing its clinical pipeline and generating revenue through its Nugevia product. Management emphasizes a disciplined approach to execution and growth.
Read more →JUNSJupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago
Jupiter Neurosciences has been invited to present its clinical and commercial progress at an exclusive investor dinner at Mar-a-Lago. The company's management will discuss advancements in its Phase IIa Parkinson's program and its commercial strategy, including the Nugevia™ product. This event highlights Jupiter's commitment to transparency and investor engagement.
Read more →JUNSJupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
Jupiter Neurosciences has amended its financing agreement with YA II PN, Ltd., deferring repayment commencement to April 2026 while maintaining core economic terms. This strategic decision supports the company's focus on its Phase II Parkinson's program and commercial efforts with Nugevia. The amendment reflects a commitment to align capital with clinical and commercial execution.
Read more →JUNS▼ -23.5%on this news
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
Jupiter Neurosciences has announced a strategic initiative to expand its Nugevia™ product line, targeting users of GLP-1 weight loss therapies. This move aims to address the physiological demands associated with GLP-1-induced weight loss, offering solutions for metabolic resilience. The company's dual-engine strategy combines a clinical pipeline with direct-to-consumer offerings, enhancing its market position.
Read more →JUNSJoin Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
Jupiter Neurosciences, Inc. is hosting a live investor webinar on January 6, 2026, to discuss its scientific platform and clinical development plans. CEO Chister Rosén will highlight the company's lead asset, JOTROL™, which is advancing toward a Phase 2a trial for Parkinson's disease. The event will also cover Jupiter's dual-path strategy in both therapeutic and consumer markets.
Read more →JUNSJupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum
Jupiter Neurosciences, Inc. has marked its first year as a public company with significant achievements, including the advancement of its JOTROL™ platform into a Phase 2a clinical trial for Parkinson's disease and the launch of its Nugevia™ consumer product line. With FDA clearance for its trial and securing up to $20 million in strategic financing, the company is focused on enhancing its position in the $8 trillion longevity market. As it enters 2026, Jupiter is poised for growth, aiming for clinical data and revenue expansion, driven by its unique scientific approach.
Read more →JUNS▲ +8.8%on this news
Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease
Jupiter Neurosciences has received FDA clearance for its IND application to start a Phase 2a clinical trial of JOTROL™ in patients with Parkinson's disease. This trial aims to evaluate the safety and tolerability of JOTROL, which has shown promising preclinical results. The company plans to begin patient enrollment in early 2026, marking a significant step forward in addressing the unmet medical needs of Parkinson's patients.
Read more →JUNS▲ +11.1%on this news
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
Jupiter Neurosciences, Inc. has entered into financing agreements potentially worth $20 million to support its Phase 2 trial for JOTROL™, aimed at treating Parkinson's disease. The funds will also be used to enhance the marketing of its Nugevia™ product line. The financing includes immediate advances and options for further capital over the next two years.
Read more →JUNS▲ +5.3%on this news
Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador
Jupiter Neurosciences has appointed Jean Fallacara as the third brand ambassador for its Nugevia™ longevity supplement line. Fallacara, a recognized biohacker and entrepreneur, emphasizes the importance of resveratrol in promoting longevity. The Nugevia™ brand aims to merge clinical research with wellness innovation, targeting the growing longevity market projected to reach $8 trillion by 2030.
Read more →JUNSJupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements
Jupiter Neurosciences has launched its Nugevia™ website and opened pre-orders for three nutraceutical supplements, leveraging its patented JOTROL™ technology. This initiative marks a significant step in the company's dual-path strategy, combining consumer health solutions with ongoing CNS therapeutic programs. The products aim to tap into the growing longevity market, with shipping expected to start in Fall 2025.
Read more →JUNSJupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador
Jupiter Neurosciences has appointed NBA legend Chris Webber as the second brand ambassador for its Nugevia™ longevity supplement line. Webber's experience and commitment to performance align with Nugevia's mission to enhance health and longevity through scientifically backed products. The brand aims to tap into the growing longevity market while supporting ongoing clinical development.
Read more →JUNSJupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience
Jupiter Neurosciences has launched Nugevia MND, a cognitive health supplement combining its proprietary JOTROL resveratrol technology with NovaSOL Curcumin. This product aims to enhance cognitive performance and support neuroprotective health, catering to the increasing consumer demand for validated cognitive wellness solutions. The supplement is set to be available through e-commerce platforms starting Fall 2025.
Read more →JUNSJupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science
Jupiter Neurosciences highlights the advantages of its JOTROL™ platform, a patented resveratrol formulation that significantly improves bioavailability and reduces gastrointestinal side effects. The company is preparing for a Phase IIa trial in Parkinson's Disease, leveraging promising preclinical data. Additionally, JOTROL™ will support the upcoming Nugevia™ consumer product line focused on cognitive health and longevity.
Read more →JUNS▲ +19.9%on this news· ran to +47% by day 1
Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jupiter Neurosciences, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, following a period where its stock maintained an average closing price above $1.00. This compliance was confirmed by Nasdaq on July 9, 2025, and reflects a positive trend in the company's stock performance. Jupiter continues to develop its JOTROL™ platform for CNS disorders and rare diseases.
Read more →JUNSJupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
Jupiter Neurosciences has introduced Nugevia™ PWR, a mitochondrial health supplement aimed at enhancing cellular energy, endurance, and recovery. This product leverages the company's proprietary JOTROL™ platform and is set to launch in Fall 2025. PWR aims to meet the increasing consumer demand for scientifically-backed supplements, positioning Jupiter for significant growth in the wellness market.
Read more →JUNSJupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
Jupiter Neurosciences has launched Nugevia GLO, a supplement aimed at enhancing skin health through scientifically validated cellular defense. Leveraging its proprietary JOTROL technology, GLO promises improved skin vitality and hydration. The product is set to enter the booming longevity market, with expectations of significant revenue growth for the company.
Read more →JUNS▲ +15.2%on this news· ran to +44% by day 3
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
Jupiter Neurosciences has officially launched Nugevia™, a new line of consumer longevity supplements. This launch is part of the company's strategy to generate immediate revenues while continuing its clinical development pipeline. Nugevia products leverage the proprietary JOTROL™ technology, enhancing resveratrol's bioavailability significantly. The first formulations are set to hit the market in Q3 2025, targeting health and wellness in the burgeoning longevity market, which is expected to reach $8 trillion by 2030.
Read more →JUNSJupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter
Jupiter Neurosciences, Inc. has released its first shareholder letter since going public, outlining its strategic roadmap for 2025. The company aims to advance its lead product, JOTROL™, into a Phase 2a clinical trial for Parkinson’s disease and expand into the consumer longevity market. This initiative is anticipated to generate near-term revenue, leveraging the growing global demand for longevity products. Jupiter has also applied for a significant NIH grant to support further trials related to Alzheimer’s disease, reflecting its commitment to addressing major health challenges.
Read more →JUNS▲ +6.1%on this news
Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products
Jupiter Neurosciences has formed a strategic collaboration with Aquanova AG to develop consumer-based nutritional products focusing on longevity and healthspan. The initial three products are projected to launch in Q3 2025, coinciding with a Direct-to-Consumer sales model aimed at generating immediate revenue growth. Leveraging the patented JOTROL formulation, which shows promising bioavailability, the partnership looks to address consumer demands in the aging health market while supporting ongoing clinical trials for CNS disorders.
Read more →JUNS▲ +11.4%on this news
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
Jupiter Neurosciences, Inc. has addressed recent market volatility, emphasizing that there are no undisclosed material developments affecting the company. It plans to launch a Direct-to-Consumer product line in 2025, which is expected to provide immediate cash flow while advancing its clinical trials for JOTROL™, a resveratrol-based treatment aimed at CNS disorders. The company is also advancing its clinical pipeline with partnerships and has secured substantial funding to support its initiatives. Jupiter remains committed to addressing neuroinflammatory diseases and promoting health solutions for aging populations.
Read more →JUNS▼ -5.8%on this newsshared move
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial
Jupiter Neurosciences has announced a manufacturing agreement with Catalent Pharma Solutions to produce JOTROL softgel capsules for its upcoming Phase 2a clinical trial in Parkinson's disease. The partnership aims to enhance efficiency in manufacturing clinical batches, including both active and placebo versions of JOTROL, which is designed to improve the bioavailability of resveratrol. With a projected market for Parkinson's therapeutics exceeding $14 billion by 2030, this initiative is a significant step in advancing JOTROL's development in neurodegenerative diseases.
Read more →JUNS▼ -8.2%on this newsshared move
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
Jupiter Neurosciences has announced a strategic partnership with Zina Biopharmaceuticals to advance its Phase 2a clinical trial of JOTROL™ for Parkinson's disease. This collaboration will involve Zina providing services crucial for trial execution, including clinical trial protocol design and regulatory strategy. JOTROL is a resveratrol-based platform designed to enhance bioavailability while minimizing gastrointestinal side effects. With over 10 million Parkinson's patients and no current disease-modifying treatments available, this trial aims to evaluate the drug's safety and effectiveness.
Read more →JUNSJupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials
Jupiter Neurosciences has announced a strategic emphasis on the NLRP3 inflammasome in its upcoming JOTROL™ clinical trials, targeting neurodegenerative diseases. The company aims to leverage JOTROL's unique formulation, which increases bioavailability and minimizes gastrointestinal side effects, to make significant advances in treating conditions like Parkinson’s and Alzheimer’s. Demand for effective Alzheimer’s treatments and the recent passage of the National Plan to End Parkinson’s Act presents a timely opportunity for the firm to expand its market engagement. Additionally, Jupiter is looking into partnerships for advancing towards addressing obesity-related conditions.
Read more →JUNSJupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
Jupiter Neurosciences, Inc. announced the successful closing of its initial public offering, raising $11 million by selling 2,750,000 shares at $4.00 each. The shares began trading on the Nasdaq Capital Market under the ticker JUNS. Proceeds from the IPO will be used to fund a Phase II clinical trial for its product candidate JOTROL™, aimed at treating Parkinson's Disease, among other uses. The company also plans to accelerate business activities in Southeast Asia and support its research and development efforts.
Read more →JUNSJupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq Jupiter, Florida
Jupiter Neurosciences, Inc. has announced the pricing of its initial public offering (IPO) of $11 million, with shares set to trade on the NASDAQ under the ticker 'JUNS' starting December 3, 2024. The IPO involves offering 2,750,000 shares at a price of $4.00 per share, which is expected to close on December 4, 2024. The proceeds will fund the Phase II clinical trial of its product candidate JOTROL in Parkinson's Disease and support other business activities, including R&D and working capital.
Read more →Competitive Position
How JUNS ranks across every disease it competes inCompetitive Position is a premium feature
See how JUNS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial